Compile Data Set for Download or QSAR
Report error Found 169 of affinity data for UniProtKB/TrEMBL: Q9ULC4
TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403235(US10329303, Example 34)
Affinity DataEC50:  1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403225(US10329303, Example 24)
Affinity DataEC50:  1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403040(US10329303, Example 6)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403239(US10329303, Example 38)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM402876(US10329303, Example 1)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403224(US10329303, Example 23)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403252(US10329303, Example 51)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403184(US10329303, Example 20)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403253(US10329303, Example 52)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403188(US10329303, Example 21)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403218(US10329303, Example 22)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403142(US10329303, Example 15)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403251(US10329303, Example 50)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403246(US10329303, Example 45)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403118(US10329303, Example 14)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403041(US10329303, Example 7)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403093(US10329303, Example 9)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403095(US10329303, Example 11)
Affinity DataEC50:  25nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403059(US10329303, Example 8)
Affinity DataEC50:  34nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403229(US10329303, Example 28)
Affinity DataEC50:  40nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476274(US10874675, Example 13)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476273(US10874675, Example 12)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476270(US10874675, Example 11)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476269(US10874675, Example 10)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476268(US10874675, Example 9)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476264(US10874675, Example 7)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476263(US10874675, Example 6)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476261(US10874675, Example 5)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476242(US10874675, Example 4)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476241(US10874675, Example 3)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476240(US10874675, Example 2)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403111(US10329303, Example 13)
Affinity DataEC50:  50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403241(US10329303, Example 40)
Affinity DataEC50:  50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM345287(2-[[1-[(2-Chlorophenyl)methyl]-5-[3- (cyclopropyl...)
Affinity DataIC50: 54.5nMAssay Description:MCT1 activity may be measured using BT-20 breast cancer cells that express high native levels of MCT1, but do not express MCT4 and are known to those...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403182(US10329303, Example 19)
Affinity DataEC50:  70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403234(US10329303, Example 33)
Affinity DataEC50:  70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403109(US10329303, Example 12)
Affinity DataEC50:  75nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403236(US10329303, Example 35)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403228(US10329303, Example 27)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403230(US10329303, Example 29)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403240(US10329303, Example 39)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403094(US10329303, Example 10)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403227(US10329303, Example 26)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403237(US10329303, Example 36)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403238(US10329303, Example 37)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476279(US10874675, Example 18)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476278(US10874675, Example 17)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM403232(US10329303, Example 31)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476277(US10874675, Example 16)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476276(US10874675, Example 15)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

Displayed 1 to 50 (of 169 total ) | Next | Last >>
Jump to: